Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia

Cody J. Peer, Tristan M. Sissung, Ae Rang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Federspiel, David Venzon, William Dahut, Elise Kohn, Shivaani Kummar, Robert Yarchoan, Giuseppe Giaccone, Brigitte Widemann, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

119 Scopus citations

Fingerprint

Dive into the research topics of 'Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia'. Together they form a unique fingerprint.

Medicine & Life Sciences